

10/583,590

=> d his

(FILE 'HOME' ENTERED AT 15:53:15 ON 09 AUG 2011)

FILE 'REGISTRY' ENTERED AT 15:53:20 ON 09 AUG 2011

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 4316 S L1 SSS FUL
L4 STRUCTURE UPLOADED
L5 3756 S L4 SUB=L3 FUL
L6 560 S L3 NOT L5

FILE 'CAPLUS' ENTERED AT 16:08:23 ON 09 AUG 2011

L7 1 S US 20090143576/PN
 SELECT RN L7 1-

FILE 'REGISTRY' ENTERED AT 16:08:44 ON 09 AUG 2011

L8 24 S E1-24
L9 13 S L8 AND NRS=1
L10 6 S L9 AND 6-7/SZ
L11 7 S L9 NOT L10
L12 46 S C11 H15 CL2 N . CL H/MF
L13 1 S L11 AND L12

FILE 'CAPLUS' ENTERED AT 16:11:01 ON 09 AUG 2011

L14 1561 S L5
L15 4 S L13
L16 2 S L14 AND L15
L17 17 S L6
L18 4 S L15 OR L16

FILE 'REGISTRY' ENTERED AT 16:12:16 ON 09 AUG 2011

L19 491 S L6 AND CAPLUS/LC
L20 69 S L6 NOT L19

FILE 'CAPLUS' ENTERED AT 16:12:51 ON 09 AUG 2011

=> d ibib abs hitstr total l17

L17 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:627117 CAPLUS

DOCUMENT NUMBER: 153:163337

TITLE: Thousands of chemical starting points for antimalarial lead identification

AUTHOR(S): Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.

CORPORATE SOURCE: Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, 28760, Spain

SOURCE: Nature (London, United Kingdom) (2010), 465(7296), 305-310

CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Malaria is a devastating infection caused by protozoa of the genus Plasmodium. Drug resistance is widespread, no new chemical class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs. We screened nearly 2 million compds. in GlaxoSmithKline's chemical library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μ M concentration. More than 8,000 also showed potent activity against the multidrug resistant strain Dd2. Most (82%) compds. originate from internal company projects and are new to the malaria community. Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets. Chemical structures and associated data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.

IT 583045-89-0

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimalarial drugs lead identification)

RN 583045-89-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS RECORD (44 CITINGS)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:82415 CAPLUS

DOCUMENT NUMBER: 152:168819

TITLE: Preparation of benzazepine derivatives for use as histamine H3 antagonists

INVENTOR(S): Pooni, Parminder Kaur; Merchant, Kevin John; Kerr, Catrina; Crosby, Stuart Richard; Okawa, Tomohiro; Sasaki, Mitsuru; Gotou, Mika; Showell, Graham Andrew; Teall, Martin Richard

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited., Japan

SOURCE: PCT Int. Appl., 188pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010007382	A1	20100121	WO 2009-GB1774	20090717
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW,				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2009272486	A1	20100121	AU 2009-272486	20090717
CA 2731196	A1	20100121	CA 2009-2731196	20090717
KR 2011036044	A	20110406	KR 2011-7001319	20090717
EP 2326625	A1	20110601	EP 2009-784728	20090717
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, AL, BA, RS				
CN 102099339	A	20110615	CN 2009-80127932	20090717
US 20110124626	A1	20110526	US 2011-54688	20110118
PRIORITY APPLN. INFO.:			GB 2008-13254	A 20080718
			GB 2009-5231	A 20090326
			WO 2009-GB1774	W 20090717


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:168819; MARPAT 152:168819

GI




- AB Title compds. I [A = OC(O), C(O)O, CO, cycloalkylene, etc.; X = absent, (un)substituted alkylene, or alkenylene; Z = (un)substituted aryl, heteroaryl, cycloalkyl, or heterocyclyl; R1 = (un)substituted cycloalkyl, alkyl, alkylene-cycloalkyl, or heterocyclyl; n = 0 to 4; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as histamine H3 antagonists. Thus, e.g., II was prepared by reductive amidation of 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[d]azepine with cyclobutanone followed by addition to tert-Bu 1-oxa-6-azaspiro[2.5]octane-6-carboxylate, deprotection, and amidation with propionyl chloride. Select I were evaluated in H3 binding assays (data given).
- IT 1204828-87-4P 1204828-88-5P 1204828-89-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzazepine derivs. for use as histamine H3 antagonists)
- RN 1204828-87-4 CAPLUS
- CN 3H-3-Benzazepine-3-carboxylic acid,
 1,2,4,5-tetrahydro-7-[(phenylsulfonyl)methyl]-, 1,1-dimethylethyl ester
 (CA INDEX NAME)




- RN 1204828-88-5 CAPLUS
- CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(phenylsulfonyl)methyl]-,
 hydrochloride (1:1) (CA INDEX NAME)

10/583,590



● HCl

RN 1204828-89-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-
[(phenylsulfonyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT:	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT:	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:1316120 CAPLUS

DOCUMENT NUMBER: 152:66477

TITLE: The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor

AUTHOR(S): Bailey, James M.; Scott, Jackie S.; Basilla, Jonathan B.; Bolton, Victoria J.; Boyfield, Izzy; Evans, David G.; Fleury, Etienne; Heightman, Tom D.; Jarvie, Emma M.; Lawless, Kirk; Matthews, Kim L.; McKay, Fiona; Mok, Hindy; Muir, Alison; Orlek, Barry S.; Sanger, Gareth J.; Stemp, Geoffrey; Stevens, Alexander J.; Thompson, Mervyn; Ward, John; Vaidya, Kalindi; Westaway, Susan M.

CORPORATE SOURCE: Immuno-Inflammation Centre of Excellence for Drug Discovery, Medicines Research Centre, GlaxoSmithKline, Stevenage, Herts, SG1 2NY, UK

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2009), 19(22), 6452-6458
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 152:66477


AB Optimization of a series of benzazepine sulfonamide hit compds. identified from high throughput screening led to the discovery of a new series of tractable, potent motilin receptor agonists.

IT	789487-55-4	1201677-67-9	1201677-68-0
	1201677-69-1	1201677-71-5	1201677-72-6
	1201677-73-7	1201677-74-8	1201677-75-9
	1201677-76-0	1201677-77-1	1201677-78-2
	1201677-79-3	1201677-82-8	1201677-83-9
	1201677-85-1	1201677-86-2	1201677-87-3
	1201677-88-4	1201678-02-5	1201678-03-6
	1201678-04-7	1201678-05-8	1201678-06-9
	1201678-09-2		

RL: PAC (Pharmacological activity); BIOL (Biological study)
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)


RN 789487-55-4 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 1201677-67-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 1201677-68-0 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(tetrahydro-3-furanyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-69-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1-methyl-4-piperidinyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-71-5 CAPLUS


CN Benzenesulfonamide, N-[3-(1-acetyl-4-piperidinyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-butyl- (CA INDEX NAME)



RN 1201677-72-6 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 1201677-73-7 CAPLUS

CN Acetamide, N-[3-[[7-[[4-(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (CA INDEX NAME)




RN 1201677-74-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(2-thienylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-75-9 CAPLUS

CN Acetamide, N-[5-[[7-[[4-(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-2-thienyl]- (CA INDEX NAME)




RN 1201677-76-0 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1H-imidazol-5-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-77-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(4-methyl-1H-imidazol-5-yl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-78-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(2-methyl-1H-imidazol-5-yl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-79-3 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(1-methyl-1H-imidazol-5-yl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-82-8 CAPLUS

CN Benzenemethanesulfonamide, N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-83-9 CAPLUS

CN Benzenesulfonamide, 4-cyano-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-85-1 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-86-2 CAPLUS


CN Benzenesulfonamide, 3-chloro-4-methyl-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-87-3 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 1201677-88-4 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethoxy)-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201678-02-5 CAPLUS

CN 1H-3-Benzazepine, 7-[[4-(4-butylphenyl)sulfonyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 1201678-03-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(phenylsulfonyl)methyl]- (CA INDEX NAME)




RN 1201678-04-7 CAPLUS

CN 1H-3-Benzazepine, 7-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)


10/583,590




RN 1201678-05-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(2-naphthalenylsulfonyl)methyl]-
(CA INDEX NAME)




RN 1201678-06-9 CAPLUS
CN 1H-3-Benzazepine, 7-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 1201678-09-2 CAPLUS
CN 1H-3-Benzazepine, 7-[[3',4'-difluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)




IT 1201677-80-6
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)
RN 1201677-80-6 CAPLUS
CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



IT 1201678-07-0P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)
 RN 1201678-07-0 CAPLUS
 CN 1H-3-Benzazepine, 7-[[[(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




IT 583025-17-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)
 RN 583025-17-6 CAPLUS
 CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT 956102-17-3P 1201678-21-8P 1201678-24-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)
 RN 956102-17-3 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/583,590



RN 1201678-21-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[4-(4-bromophenyl)sulfonyl]methyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 1201678-24-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[4'-(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2009:322791 CAPLUS
 DOCUMENT NUMBER: 150:554899
 TITLE: 7-Sulfonamido-3-benzazepines as potent and selective
 5-HT_{2C} receptor agonists: Hit-to-lead optimization
 AUTHOR(S): Fish, Paul V.; Brown, Alan D.; Evrard, Edel; Roberts,
 Lee R.
 CORPORATE SOURCE: Discovery Chemistry, Sandwich Laboratories, Pfizer
 Global Research and Development, Sandwich, Kent, CT13
 9NJ, UK
 SOURCE: Bioorganic & Medicinal
 Chemistry Letters (2009),
 19(7), 1871-1875
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 150:554899
 GI



AB New 7-sulfonamido-3-benzazepines (I) are disclosed as 5-HT_{2C} receptor agonists. Appropriate substitution of the amino group (R₁R₂N-) gave compds. that were potent 5-HT_{2C} agonists with minimal activation of the 5-HT_{2A} and 5-HT_{2B} receptors. Furthermore, representative examples had excellent in vitro ADME properties and good selectivity over ion channel activity.


IT 1154438-36-4P 1154438-38-6P 1154438-40-0P
 1154438-47-7P 1154438-95-5P 1154438-97-7P
 1154438-99-9P 1154439-01-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(7-sulfonamido-3-benzazepines as potent and selective 5-HT_{2C} receptor agonists in hit-to-lead optimization program)

RN 1154438-36-4 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-phenyl- (CA INDEX NAME)



10/583,590


RN 1154438-38-6 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, N-(2-fluorophenyl)-2,3,4,5-tetrahydro-
(CA INDEX NAME)




RN 1154438-40-0 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, N-(2-chlorophenyl)-2,3,4,5-tetrahydro-
(CA INDEX NAME)




RN 1154438-47-7 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-methyl-N-phenyl- (CA
INDEX NAME)



RN 1154438-95-5 CAPLUS


CN Benzenesulfonamide, 2-fluoro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-
(CA INDEX NAME)



RN 1154438-97-7 CAPLUS


CN Benzenesulfonamide, 2-fluoro-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-
benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 1154438-99-9 CAPLUS

CN Benzenemethanesulfonamide, 4-fluoro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 1154439-01-6 CAPLUS

CN Benzenemethanesulfonamide, 4-fluoro-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:1249178 CAPLUS

DOCUMENT NUMBER: 150:252

TITLE: Tricyclic azepine derivatives as selective brain penetrant 5-HT₆ receptor antagonists

AUTHOR(S): Trani, Giancarlo; Baddeley, Stuart M.; Briggs, Michael A.; Chuang, Tsu T.; Deeks, Nigel J.; Johnson, Christopher N.; Khazragi, Abir A.; Mead, Tania L.; Medhurst, Andrew D.; Milner, Peter H.; Quinn, Leann P.; Ray, Alison M.; Rivers, Dean A.; Stean, Tania O.; Stemp, Geoffrey; Trail, Brenda K.; Witty, David R.

CORPORATE SOURCE: Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2008),

18(20), 5698-5700

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Starting from a benzazepine sulfonamide 5-HT₆ receptor antagonist lead with limited brain penetration, application of a strategy of conformational constraint and reduction of hydrogen bond donor count led to a novel series of tricyclic derivs. with high 5-HT₆ receptor affinity and excellent brain:blood ratios.

IT 1087197-72-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(tricyclic azepine derivs. as selective brain penetrant 5-HT₆ receptor antagonists)

RN 1087197-72-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[(phenylsulfonyl)amino]-8-[2-(trimethylsilyl)ethynyl]-
, 1,1-dimethylethyl ester (CA INDEX NAME)


IT 585570-84-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tricyclic azepine derivs. as selective brain penetrant 5-HT₆ receptor antagonists)

RN 585570-84-9 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT:	10	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:881207 CAPLUS
 DOCUMENT NUMBER: 149:168025
 TITLE: Use of 5-HT6 antagonists to prevent relapse into addiction
 INVENTOR(S): De Bruin, Natasja M. W. J.; Van Loevezijn, Arnold;
 Wijnen, Johan; Herremans, Arnoldus H. J.; Kruse,
 Cornelis G.
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
 SOURCE: PCT Int. Appl., 28pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008087123	A2	20080724	WO 2008-EP50360	20080115
WO 2008087123	A3	20081127		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AR 64860	A1	20090429	AR 2008-100125	20080111
PRIORITY APPLN. INFO.:			EP 2007-100576	A 20070116
			US 2007-880421P	P 20070116

OTHER SOURCE(S): MARPAT 149:168025


AB The invention discloses the use of compds., and pharmaceutically acceptable salts thereof, which are 5-HT6 antagonists. These compds. are useful for the preparation of medicaments for preventing relapse into addiction, in particular relapse into addiction to substances of abuse, including opiates, hallucinogens, inhalants, phencyclidine, amphetamines, cocaine, cannabis, nicotine, and alc., into relapse to addiction to certain medicines, including sedatives, hypnotics and anxiolytics, and into relapse to certain addictive behaviors, including gambling.

IT 583045-76-5, SB 737050A 583045-76-5D, SB 737050A, stereoisomers, tautomers, N-oxides, isotopically labeled analogs, or salts
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (5-HT6 antagonists for prevention of relapse into addiction)

RN 583045-76-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



RN 583045-76-5 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:858203 CAPLUS

DOCUMENT NUMBER: 149:144007

TITLE: Use of 5-HT6 antagonists to prevent relapse into addiction

INVENTOR(S): De Bruin, Natasja M. W. J.; Van Loevezijn, Arnold; Wijnen, Johan; Herremans, Arnoldus H. J.; Kruse, Cornelis G.

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: U.S. Pat. Appl. Publ., 15pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20080171779	A1	20080717	US 2008-13898	20080114
PRIORITY APPLN. INFO.:			US 2007-880421P	P 20070116

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:144007

AB The invention discloses the use of compds., and pharmaceutically acceptable salts thereof, which are 5-HT6 antagonists. In one embodiment, the invention relates to the use of these compds., or pharmaceutical compns. comprising these compds., for preventing relapse into addiction, e.g. relapse into addiction to substances of abuse, including opiates, hallucinogens, inhalants, phencyclidine, amphetamines, cocaine, cannabis, nicotine, and alc., relapse into addiction to certain medicines, including sedatives, hypnotics and anxiolytics, and relapse into certain addictive behaviors, including gambling.


IT 583045-76-5, SB 737050A 583045-76-5D, tautomers, stereoisomers, N-oxides, salts, and isotopically labeled analogs

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(5-HT6 antagonists to prevent relapse into addiction)

RN 583045-76-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-76-5 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:411959 CAPLUS

DOCUMENT NUMBER: 148:403094

TITLE: Preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunological diseases

INVENTOR(S): Lawton, Geoff; Kozlowski, Roland; Hogg, Dayle

PATENT ASSIGNEE(S): Lectus Therapeutics Limited, UK

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038051	A2	20080403	WO 2007-GB50591	20070928
WO 2008038051	A3	20080619		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
WO 2008038053	A1	20080403	WO 2007-GB50593	20070928
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2066317	A2	20090610	EP 2007-804494	20070928
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
EP 2069309	A1	20090617	EP 2007-804496	20070928
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2010504953	T	20100218	JP 2009-529780	20070928
JP 2010504954	T	20100218	JP 2009-529781	20070928
US 20110130383	A1	20110602	US 2009-443396	20090327
US 20090318423	A1	20091224	US 2009-443402	20090414
PRIORITY APPLN. INFO.:			GB 2006-19176	A 20060929



WO 2007-GB50591 W 20070928

WO 2007-GB50593 W 20070928

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:403094; MARPAT 148:403094

GI



AB The title compds. I [A and B = CH₂ or CH₂CH₂; R₁ = H, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl; R₂-R₄ = H, alkyl, halo, haloalkyl, alkoxy, alkoxy carbonyl, carboxyl, hydroxyl or cyano; X = R₅CO, R₅SO₂, R₅R₇NCO, R₅R₇NSO₂, R₅SO₂NR₇CO or CO₂R₈; Y = R₆CO, R₆SO₂, R₆R₇NCO, R₆R₇NSO₂, R₆SO₂NR₇CO or CO₂R₈; R₅ and R₆ = H, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R₇ = H, alkyl, aryl or aralkyl; R₈ = alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl; provided that when X is R₅CO or R₅SO₂, then Y is not R₆CO, R₆SO₂ or R₆R₇NCO], useful in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunol. disease (alone or in combination with other therapeutic agents), were prepared. Thus, treating 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine with trimethylsilyl isocyanate in CHCl₃ followed by the addition of p-toluenesulfonyl isocyanate afforded II as triethylamine salt.

IT 1016265-22-7P 1016265-57-8P 1016265-59-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunol. diseases)

RN 1016265-22-7 CAPLUS


CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-7-[(phenylsulfonyl)amino]- (CA INDEX NAME)

10/583,590




RN 1016265-57-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-7-[[4-methylphenyl)sulfonyl]amino]- (CA INDEX NAME)



RN 1016265-59-0 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 7-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]-1,2,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



IT 585570-84-9P 585570-87-2P 1016265-95-4P


1016266-36-6P 1016266-39-9P 1016266-41-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunol. diseases)

RN 585570-84-9 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 585570-87-2 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-
(CA INDEX NAME)




RN 1016265-95-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[(phenylsulfonyl)amino]-, phenylmethyl ester (CA
INDEX NAME)



RN 1016266-36-6 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[[(4-methylphenyl)sulfonyl]amino]-, phenylmethyl
ester (CA INDEX NAME)



RN 1016266-39-9 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,2,4,5-tetrahydro-, phenylmethyl
ester (CA INDEX NAME)

10/583,590



RN 1016266-41-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-
(CA INDEX NAME)



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:1469363 CAPLUS

DOCUMENT NUMBER: 148:93272

TITLE: Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity, and therapeutic use

INVENTOR(S): Codony-Soler, Xavier; Buschmann, Helmut Henrich

PATENT ASSIGNEE(S): Laboratorios Del Dr. Esteve, S.A., Spain

SOURCE: PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007147883	A1	20071227	WO 2007-EP56234	20070622
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2658959	A1	20071227	CA 2007-2658959	20070622
EP 2040755	A1	20090401	EP 2007-765553	20070622
EP 2040755	B1	20110518		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009541423	T	20091126	JP 2009-517134	20070622
AT 509636	T	20110615	AT 2007-765553	20070622
IN 2008KN05064	A	20090327	IN 2008-KN5064	20081212
MX 2008015996	A	20090120	MX 2008-15996	20081215
CN 101500611	A	20090805	CN 2007-80025116	20081231
US 20100120747	A1	20100513	US 2009-305516	20090326
PRIORITY APPLN. INFO.:			EP 2006-384012	A 20060623
			WO 2007-EP56234	W 20070622

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:93272

AB The invention discloses a combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, as well as a medicament comprising the combination, and the use of the combination for the manufacture of a medicament.

IT 585570-88-3 585570-88-3D, enantiomers and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(cholinesterase inhibitor combination with compound with 5-HT6 receptor affinity)

RN 585570-88-3 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-


10/583,590

yl)- (CA INDEX NAME)



RN 585570-88-3 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:1356517 CAPLUS

DOCUMENT NUMBER: 148:92237

TITLE: New Serotonin 5-HT6 Ligands from Common Feature Pharmacophore Hypotheses

AUTHOR(S): Kim, Hye-Jung; Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seo; No, Kyoung Tai; Park, Woo-Kyu; Pae, Ae Nim

CORPORATE SOURCE: Life Science Division, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea

SOURCE: Journal of Chemical Information and Modeling (2008), 48(1), 197-206

CODEN: JCISD8; ISSN: 1549-9596

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Serotonin 5-HT6 receptor antagonists are thought to play an important role in the treatment of psychiatry, Alzheimer's disease, and probably obesity. To find novel and potent 5-HT6 antagonists and to provide a new idea for drug design, we used a ligand-based pharmacophore to perform the virtual screening of a com. available database. A three-dimensional common feature pharmacophore model was developed by using the HipHop program provided in Catalyst software and was used as a query for screening the database. A recursive partitioning (RP) model which can sep. active and inactive compds. was used as a filtering system. Finally a sequential virtual screening procedure (SQSP) was conducted, wherein both the common feature pharmacophore and the RP model were used in succession to improve the results. Some of the hits were selected based on druglikeness, ADME properties, structural diversity, and synthetic accessibility for real biol. evaluation. The best hit compound showed a significant IC50 value of 9.6 nM and can be used as a lead for further drug development.


IT 585570-88-3

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug design, structure-activity profile and a sequential virtual screening procedure for new serotonin 5-HT6 ligands from common feature pharmacophore hypotheses)

RN 585570-88-3 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:79574 CAPLUS

DOCUMENT NUMBER: 146:197771

TITLE: Studies towards the identification of a new generation of atypical antipsychotic agents

AUTHOR(S): Garzys, Vincenzo; Forbes, Ian T.; Gribble, Andrew D.; Hadley, Mike S.; Lightfoot, Andrew P.; Payne, Andrew H.; Smith, Alexander B.; Douglas, Sara E.; Cooper, David G.; Stansfield, Ian G.; Meeson, Malcom; Dodds, Emma E.; Jones, Declan N. C.; Wood, Martyn; Reavill, Charlie; Scorer, Carol A.; Worby, Angela; Riley, Graham; Eddershaw, Peter; Ioannou, Chris; Donati, Daniele; Hagan, Jim J.; Ratti, Emiliangelo A.

CORPORATE SOURCE: New Frontiers Science Park, Psychiatry Centre of Excellence for Drug Discovery, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal

Chemistry Letters (2007), 17(2), 400-405

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:197771

GI



I


AB A lead optimization program led to the identification of sulfonamide I (25), a mol. combining dopamine D2/D3 receptor antagonism with serotonin 5-HT2A, 5-HT2C, 5-HT6 receptor antagonism for an effective treatment of schizophrenia. Compound I was shown to possess the required in vivo activity with no EPS liability.

IT 583025-17-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(heterocyclic sulfonamides as dopamine and serotonin receptor antagonists)

RN 583025-17-6 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-
(CA INDEX NAME)




IT 583025-18-7P 583044-70-6P 583044-97-7P
 583045-11-8P 583045-89-0P 583046-87-1P
 583047-05-6P 753447-17-5P 923573-88-0P
 923573-89-1P 923573-90-4P 923573-91-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heterocyclic sulfonamides as dopamine and serotonin receptor antagonists)


RN 583025-18-7 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-70-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-97-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 583045-11-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-89-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-87-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583047-05-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 753447-17-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 923573-88-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-4'-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 923573-89-1 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 923573-90-4 CAPLUS

CN Benzenesulfonamide, 4-(3,5-dimethyl-4-isoxazolyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 923573-91-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




IT 583044-69-3P 583044-96-6P 583045-88-9P
 583047-45-4P 732982-31-9P 755750-84-6P
 783302-10-3P 956102-17-3P 956103-24-5P
 956115-77-8P 956115-81-4P 956116-16-8P
 956116-94-2P 956126-02-6P 956126-06-0P
 956126-17-3P 956126-23-1P 956126-84-4P
 956127-01-8P 956127-02-9P 956127-28-9P
 956140-80-0P 956141-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(heterocyclic sulfonamides as dopamine and serotonin receptor antagonists)


RN 583044-69-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-96-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-88-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583047-45-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-8-(dimethylamino)-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 732982-31-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-
1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 755750-84-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-
tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 783302-10-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-1H-
3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956102-17-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl
ester (CA INDEX NAME)




RN 956103-24-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 956115-77-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 956115-81-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-4'-fluoro-N-(2,3,4,5-tetrahydro-
1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956116-16-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4'-(2-chloro-3-fluorophenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-
1,1-dimethylethyl ester (CA INDEX NAME)




RN 956116-94-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4'-(4-chloro-2-methylphenyl)sulfonyl]amino]-1,2,4,5-
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956126-02-6 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[[[4-(5-methyl-2-thienyl)phenyl]sulfonyl]amino]-,
1,1-dimethylethyl ester (CA INDEX NAME)



10/583,590


RN 956126-06-0 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956126-17-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[4-(3,5-dimethyl-4-isoxazolyl)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956126-23-1 CAPLUS


CN Benzenesulfonamide, 4-(3,5-dimethyl-4-isoxazolyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 956126-84-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[4'-(4-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)






RN 956127-01-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956127-02-9 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-(1-methylethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956127-28-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-8-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 956140-80-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590



RN 956141-98-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[4'-chloro[1,1'-biphenyl]-4-yl]sulfonylamino]-1,2,4,5-tetrahydro-8-(1-methylethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT:	20	THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
REFERENCE COUNT:	27	THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:570815 CAPLUS

DOCUMENT NUMBER: 143:97282

TITLE: Tetrahydrobenzazepines as dopamine D3 receptor modulators, their preparation, pharmaceutical compositions and use in the treatment of CNS disorders and renal function disorders

INVENTOR(S): Braje, Wilfried; Haupt, Andreas; Lubisch, Wilfried; Grandel, Roland; Drescher, Karla; Geneste, Herve; Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. &

Co. K.-G., Germany

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058328	A1	20050630	WO 2004-EP14428	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050137186	A1	20050623	US 2003-740092	20031218
CA 2550053	A1	20050630	CA 2004-2550053	20041217
EP 1694334	A1	20060830	EP 2004-820441	20041217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007514696	T	20070607	JP 2006-544363	20041217
MX 2006006858	A	20060904	MX 2006-6858	20060616
US 20090105224	A1	20090423	US 2008-583590	20081212
PRIORITY APPLN. INFO.:			US 2003-530806P	P 20031218
			US 2003-740092	A 20031218
			WO 2004-EP14428	W 20041217
OTHER SOURCE(S):	CASREACT 143:97282; MARPAT 143:97282			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to tetrahydrobenzazepines I, which are selective modulators of dopamine D3 receptors. In compds. I, A is a bond or CH₂; B is a bond or (un)substituted N; Y is a bond, CH₂, or (un)substituted N, where A, B, and Y are not simultaneously a bond; Ar is (un)substituted aryl or (un)substituted 5- or 6-membered heteroaryl containing 1-4 heteroatoms

independently selected from O, N, and S; R1 is (un)substituted C1-8 alkyl, H, C1-8 haloalkyl, C2-8 alkenyl, etc.; and R2 is H, halo, C1-4 alkyl, C1-4 alkoxy, OH, nitro, cyano, etc.; including the corresponding N-oxides of I and all physiol. tolerated acid addition salts. The invention also relates to pharmaceutical compns. that comprise at least one tetrahydrobenzazepine I, the physiol. tolerated acid addition salt of I, the N-oxide of compound I and/or the physiol. tolerated acid addition salts of the N-oxides of I, together with physiol. acceptable carriers and/or excipients, as well as to the use of compound I for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 receptor agonists. The compds. of the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

1,2-Benzenediacetic acid was esterified, followed by reduction, mesylation and heterocyclization with n-propylamine to give benzazepine II. II underwent carboxylation with oxalyl chloride and hydride reduction to give alc. III. Chlorination of III followed by substitution with (4-isopropyl)thiophenol, oxidation to the sulfone, and salt formation with hydrochloric acid resulted in the formation of compound IV. The compds. of the invention have a high affinity for dopamine D3 receptors with many of the compds. exhibiting Ki values lower than 5 nM, and many of them having a 100-fold selectivity for D3 receptors over D2L receptors [Ki(D2L)/Ki(D3)]. Compound IV has a Ki value for binding to dopamine D3 receptors of 1 nM and 446-fold selectivity for D3 over D2L.


- IT 583025-28-9P, 4-Isopropyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide 854679-46-2P,
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-trifluoromethoxybenzenesulfonamide 854679-69-9P,
 4-Isopropyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854681-16-6P,
 N-[3-(Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide 854681-32-6P,
 N-[3-(Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide 854681-36-0P,
 4-Isopropyl-N-[3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]benzenesulfonamide 854681-39-3P,
 N-(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide 854681-42-8P,
 N-(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)
 RN 583025-28-9 CAPLUS
 CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 854679-46-2 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854679-69-9 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-16-6 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 854681-32-6 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 854681-36-0 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 854681-39-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-42-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



IT 854679-50-8P, 4-Chloro-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide 854679-54-2P,
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-vinylbenzenesulfonamide hydrochloride 854679-58-6P,
 4-Ethyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854679-62-2P,
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-

(trifluoromethyl)benzenesulfonamide hydrochloride 854679-66-6P
 , 4-tert-Butyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854679-73-5P,
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854679-77-9P,
 4-Acetyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide 854679-82-6P,
 4-Methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854679-87-1P,
 2,4,6-Trimethyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854679-92-8P,
 4-(1,1-Dimethylpropyl)-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854679-97-3P,
 3-Chloro-4-methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-02-7P,
 4-Methoxy-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-07-2P,
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)naphthalene-2-sulfonamide trifluoroacetate 854680-12-9P,
 2,4-Dichloro-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-17-4P,
 4-Bromo-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-23-2P,
 4-Bromo-2-methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-36-7P,
 N-(3-Cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854680-40-3P
 , N-(3-Cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide 854680-44-7P,
 N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854680-48-1P
 , N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide 854680-52-7P,
 N-[3-(1-Ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854680-56-1P
 , N-[3-(1-Ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854680-60-7P
 , 4-(Trifluoromethoxy)-N-[3-(3,3,3-trifluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]benzenesulfonamide hydrochloride 854680-64-1P
 , 4-(Trifluoromethyl)-N-[3-(3,3,3-trifluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]benzenesulfonamide 854680-69-6P,
 4-Isopropyl-N-methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-77-6P,
 N-Methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-trifluoromethoxybenzenesulfonamide 854680-81-2P,
 N-Phenyl-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide hydrochloride 854680-89-0P,
 N-Methyl-N-phenyl-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide hydrochloride 854680-93-6P,
 3-Propyl-N-[4-(trifluoromethoxy)phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide hydrochloride 854680-97-0P,
 7-(4-Isopropylbenzenesulfonylmethyl)-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine 854681-49-5P,
 N-[3-(2-Methylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-56-4P
 , N-[3-(4,4,4-Trifluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide 854681-60-0P,

N-[3-(4,4,4-Trifluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854681-64-4P
 , N-(3-Isobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-68-8P
 , N-[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-72-4P
 , N-(3-Ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-76-8P
 , N-[3-[3-(Cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-80-4P
 , N-[3-[3-(Cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride 854681-84-8P,
 N-[3-(2-Methoxyethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-88-2P
 , N-[3-(3-Methoxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-92-8P
 , N-[3-[2-(4-Fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-96-2P
 , N-[3-(3-Phenylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-00-1P
 , N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride 854682-05-6P,
 4-Isopropyl-N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854682-08-9P,
 N-(3-Cyclopropylmethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-isopropylbenzenesulfonamide hydrochloride 854682-12-5P,
 N-(3-Allyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-19-2P
 , N-(3-Prop-2-ynyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-23-8P
 , N-[3-(3-Fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-26-1P
 , N-[3-(3-Phenoxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-31-8P
 , N-[3-(2,2-Difluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-34-1P
 , N-[3-(4-Fluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-38-5P
 , N-(3-Butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-41-0P
 , N-(3-Allyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(isopropyl)benzenesulfonamide hydrochloride 854682-44-3P,
 N-[3-(3-Fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride 854682-46-5P,
 N-[3-(2-Fluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 856675-39-3P
 , N-[4-[(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]acetamide hydrochloride 856675-42-8P,
 4-Butyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)

RN 854679-50-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-


10/583,590

benzazepin-7-yl)- (CA INDEX NAME)



RN 854679-54-2 CAPLUS


CN Benzenesulfonamide, 4-ethenyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854679-58-6 CAPLUS

CN Benzenesulfonamide, 4-ethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854679-62-2 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854679-66-6 CAPLUS
CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854679-73-5 CAPLUS
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854679-77-9 CAPLUS
CN Benzenesulfonamide, 4-acetyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)


10/583,590



RN 854679-82-6 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 854679-81-5
CMF C20 H26 N2 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 854679-87-1 CAPLUS
CN Benzenesulfonamide, 2,4,6-trimethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-86-0
CMF C22 H30 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854679-92-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-91-7


CMF C24 H34 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/583,590


RN 854679-97-3 CAPLUS

CN Benzenesulfonamide, 3-chloro-4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-96-2


CMF C20 H25 Cl N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-02-7 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-01-6

CMF C20 H26 N2 O3 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/583,590




RN 854680-07-2 CAPLUS

CN 2-Naphthalenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-06-1


CMF C23 H26 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-12-9 CAPLUS


CN Benzenesulfonamide, 2,4-dichloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-11-8

CMF C19 H22 Cl2 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-17-4 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-16-3


CMF C19 H23 Br N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-23-2 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-


10/583,590

benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-22-1


CMF C20 H25 Br N2 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 854680-36-7 CAPLUS

CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-40-3 CAPLUS


CN Benzenesulfonamide, N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590



RN 854680-44-7 CAPLUS


CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-48-1 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854680-52-7 CAPLUS

CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/583,590

RN 854680-56-1 CAPLUS


CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-60-7 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-64-1 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 854680-69-6 CAPLUS

CN Benzenesulfonamide, N-methyl-4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


10/583,590

CRN 854680-68-5
CMF C23 H32 N2 O2 S




CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 854680-77-6 CAPLUS
CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854680-81-2 CAPLUS
CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/583,590

RN 854680-89-0 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-methyl-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-93-6 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-propyl-N-[4-(trifluoromethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-97-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-3-propyl- (CA INDEX NAME)



RN 854681-49-5 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylbutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-56-4 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-60-0 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-64-4 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-68-8 CAPLUS
CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-72-4 CAPLUS
CN Benzenesulfonamide, N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-76-8 CAPLUS
CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-80-4 CAPLUS
CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-84-8 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methoxyethyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-88-2 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-methoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-92-8 CAPLUS
CN Benzenesulfonamide, N-[3-[2-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-96-2 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-00-1 CAPLUS
CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 854682-05-6 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-08-9 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854682-12-5 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-19-2 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propyn-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-23-8 CAPLUS
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-26-1 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-31-8 CAPLUS
CN Benzenesulfonamide, N-[3-(2,2-difluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-34-1 CAPLUS
CN Benzenesulfonamide, N-[3-(4-fluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-38-5 CAPLUS
CN Benzenesulfonamide, N-(3-butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-41-0 CAPLUS
CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-44-3 CAPLUS
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-46-5 CAPLUS
CN Benzenesulfonamide, N-[3-(2-fluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 856675-39-3 CAPLUS

CN Acetamide, N-[4-[(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 856675-42-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 583025-43-8

CMF C23 H32 N2 O2 S




CM 2


CRN 76-05-1

CMF C2 H F3 O2

10/583,590



IT 854682-48-7P, N-[3-(Fluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)
RN 854682-48-7 CAPLUS
CN Benzenesulfonamide, N-[3-(2-fluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:547254 CAPLUS

DOCUMENT NUMBER: 143:59852

TITLE: A preparation of tetrahydrobenzazepine derivatives,
useful as dopamine D3 receptor ligandsINVENTOR(S): Braje, Wilfried M.; Haupt, Andreas; Lubisch, Wilfried;
Grandel, Roland; Drescher, Karla; Geneste, Herve;
Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. &

Co. Kg., Germany

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050137186	A1	20050623	US 2003-740092	20031218
CA 2550053	A1	20050630	CA 2004-2550053	20041217
WO 2005058328	A1	20050630	WO 2004-EP14428	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1694334	A1	20060830	EP 2004-820441	20041217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007514696	T	20070607	JP 2006-544363	20041217
EP 2332543	A1	20110615	EP 2010-193184	20041217
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
MX 2006006858	A	20060904	MX 2006-6858	20060616
US 20090105224	A1	20090423	US 2008-583590	20081212
PRIORITY APPLN. INFO.:			US 2003-530806P	P 20031218
			US 2003-740092	A 20031218
			EP 2004-820441	A3 20041217
			WO 2004-EP14428	W 20041217
OTHER SOURCE(S):	CASREACT 143:59852; MARPAT 143:59852			
GI				



AB The invention relates to a preparation of tetrahydrobenzazepines of formula I [wherein: A is a single bond or CH₂; B is a single bond, NH, or N(alkyl), etc.; Y is a single bond, CH₂, NH, or n(alkyl), etc.; Ar is (hetero)aryl; R₁ is H, (halo)alkyl, or alk(en/yn)yl, etc.; R₂ is H, halogen, (halo)alkyl, or alkoxy, etc.], useful as dopamine D₃ receptor ligands. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, phys. tolerated acid addition salt of I, N-oxide of compound of the formula I and/or phys. tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D₃ receptor antagonists or dopamine D₃ agonists. The compds. according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders. For instance, tetrahydrobenzazepine derivative II [K_i(D₃) = 4.1 nM] was prepared via amidation of 4-chlorobenzenesulfonyl chloride by 3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-amine.

IT 856675-42-8

RL: PRPH (Prophetic)

(A preparation of tetrahydrobenzazepine derivatives, useful as dopamine D₃ receptor ligands)


RN 856675-42-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 583025-43-8


CMF C23 H32 N2 O2 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2



IT 854680-73-2P 854681-16-6P 854681-39-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D3 receptor ligands)
 RN 854680-73-2 CAPLUS
 CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 854681-16-6 CAPLUS
 CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-39-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)




IT	583025-28-9P	854679-39-3P	854679-46-2P
	854679-50-8P	854679-54-2P	854679-58-6P
	854679-62-2P	854679-66-6P	854679-69-9P
	854679-73-5P	854679-77-9P	854679-82-6P
	854679-87-1P	854679-92-8P	854679-97-3P
	854680-02-7P	854680-07-2P	854680-12-9P
	854680-17-4P	854680-23-2P	854680-36-7P
	854680-40-3P	854680-44-7P	854680-48-1P
	854680-52-7P	854680-56-1P	854680-60-7P
	854680-64-1P	854680-69-6P	854680-77-6P
	854680-81-2P	854680-89-0P	854680-93-6P
	854680-97-0P	854681-12-2P	854681-32-6P
	854681-36-0P	854681-42-8P	854681-49-5P
	854681-56-4P	854681-60-0P	854681-64-4P
	854681-68-8P	854681-72-4P	854681-76-8P
	854681-80-4P	854681-84-8P	854681-88-2P
	854681-92-8P	854681-96-2P	854682-00-1P
	854682-05-6P	854682-08-9P	854682-12-5P
	854682-19-2P	854682-23-8P	854682-26-1P
	854682-31-8P	854682-34-1P	854682-38-5P
	854682-41-0P	854682-44-3P	854682-46-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D3 receptor ligands)


RN 583025-28-9 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 854679-39-3 CAPLUS

CN Acetamide, N-[4-[(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]- (CA INDEX NAME)




RN 854679-46-2 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 854679-50-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 854679-54-2 CAPLUS

CN Benzenesulfonamide, 4-ethenyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854679-58-6 CAPLUS


CN Benzenesulfonamide, 4-ethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854679-62-2 CAPLUS
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854679-66-6 CAPLUS
CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854679-69-9 CAPLUS
CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854679-73-5 CAPLUS
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854679-77-9 CAPLUS
CN Benzenesulfonamide, 4-acetyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 854679-82-6 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-81-5
CMF C20 H26 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854679-87-1 CAPLUS

CN Benzenesulfonamide, 2,4,6-trimethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-86-0


CMF C22 H30 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854679-92-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-3-propyl-


10/583,590

1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-91-7


CMF C24 H34 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854679-97-3 CAPLUS

CN Benzenesulfonamide, 3-chloro-4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-96-2

CMF C20 H25 Cl N2 O2 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/583,590




RN 854680-02-7 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-01-6


CMF C20 H26 N2 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-07-2 CAPLUS


CN 2-Naphthalenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-06-1

CMF C23 H26 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-12-9 CAPLUS

CN Benzenesulfonamide, 2,4-dichloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-11-8


CMF C19 H22 Cl2 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-17-4 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-


10/583,590

7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-16-3


CMF C19 H23 Br N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-23-2 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-22-1

CMF C20 H25 Br N2 O2 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/583,590



RN 854680-36-7 CAPLUS


CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-40-3 CAPLUS

CN Benzenesulfonamide, N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854680-44-7 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-48-1 CAPLUS


10/583,590

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854680-52-7 CAPLUS


CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-56-1 CAPLUS

CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-60-7 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 854680-64-1 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 854680-69-6 CAPLUS

CN Benzenesulfonamide, N-methyl-4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-68-5

CMF C23 H32 N2 O2 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/583,590




RN 854680-77-6 CAPLUS

CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854680-81-2 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-89-0 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-methyl-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/583,590

RN 854680-93-6 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-propyl-N-[4-(trifluoromethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-97-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-3-propyl- (CA INDEX NAME)



RN 854681-12-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-32-6 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590




RN 854681-36-0 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 854681-42-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854681-49-5 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylbutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-56-4 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-


10/583,590

benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-60-0 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-64-4 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-68-8 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 854681-72-4 CAPLUS


CN Benzenesulfonamide, N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-76-8 CAPLUS

CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-80-4 CAPLUS


CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-84-8 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methoxyethyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-88-2 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-methoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-92-8 CAPLUS
CN Benzenesulfonamide, N-[3-[2-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-96-2 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-00-1 CAPLUS
CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-05-6 CAPLUS
CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-08-9 CAPLUS
CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854682-12-5 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854682-19-2 CAPLUS
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propyn-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854682-23-8 CAPLUS
 CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-26-1 CAPLUS
 CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-31-8 CAPLUS
 CN Benzenesulfonamide, N-[3-(2,2-difluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-34-1 CAPLUS
CN Benzenesulfonamide, N-[3-(4-fluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-38-5 CAPLUS
CN Benzenesulfonamide, N-(3-butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-41-0 CAPLUS
CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-44-3 CAPLUS
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-46-5 CAPLUS
CN Benzenesulfonamide, N-[3-(2-fluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 854682-48-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D₃ receptor ligands)
RN 854682-48-7 CAPLUS
CN Benzenesulfonamide, N-[3-(2-fluoroacetyl)-2,3,4,5-tetrahydro-1H-3-

10/583,590

benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:913145 CAPLUS

DOCUMENT NUMBER: 139:395835

TITLE: Preparation of
N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)
benzenesulfonamides as dopamine receptor modulators
for use as antipsychotic agents

INVENTOR(S): Gribble, Andrew Derrick; Forbes, Ian Thomson;
Lightfoot, Andrew; Payne, Andrew H.; Cooper, David
Gwyn

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003095428	A1	20031120	WO 2003-GB1983	20030509
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003227919	A1	20031111	AU 2003-227919	20030509
EP 1503989	A1	20050209	EP 2003-725384	20030509
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005532318	T	20051027	JP 2004-503446	20030509
US 20070043026	A1	20070222	US 2005-513919	20050523
PRIORITY APPLN. INFO.:			GB 2002-10762	A 20020510
			WO 2003-GB1983	W 20030509

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:395835

GI




AB The title compds. [I; A, B = (CH₂)_m, (CH₂)_n; R₁ = H, alkyl; R₂ = H, halo, OH, CN, NO₂, alkyl, aryl, etc.; R₃ = H, alkyl; R₄ = (un)substituted (hetero)aryl; R₅, R₆ = H, halo, OH, CN, NO₂, alkyl, aryl, heteroaryl, etc.; m, n = 1-2; and either: Z = CR₉R₁₀X or XCR₉R₁₀ and X = O, S, SO or SO₂, or Z = CONR₁₁ or NR₉CO and X = CH₂, O, S, SO or SO₂; R₉, R₁₀ = H, alkyl, F; R₁₁ = H, alkyl] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared. Thus, amidation of 4-benzyloxybenzenesulfonyl chloride with tert-Bu 7-amino-8-bromo-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylate (preparation given) followed by Boc-group removal afforded II. The compds. I have been found to exhibit affinity for dopamine receptors, in particular the D₃ and D₂ receptors (data given), and are useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions. Addnl., certain compds. I have antagonist affinity for the serotonin 5-HT_{2C}, 5-HT_{2A} and 5-HT₆ receptors (data given). Pharmaceutical composition comprising the compound I is claimed.


IT 625813-81-2P 625813-89-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl) benzenesulfonamides as dopamine receptor modulators for use as antipsychotic agents)

RN 625813-81-2 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenoxy)methyl]-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 625813-89-0 CAPLUS
 CN Benzenesulfonamide, 4-[[(4-chlorophenyl)amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT	625813-02-7P	625813-03-8P	625813-04-9P
	625813-05-0P	625813-06-1P	625813-07-2P
	625813-08-3P	625813-09-4P	625813-12-9P
	625813-13-0P	625813-14-1P	625813-15-2P
	625813-16-3P	625813-19-6P	625813-20-9P
	625813-21-0P	625813-22-1P	625813-23-2P
	625813-24-3P	625813-25-4P	625813-26-5P
	625813-27-6P	625813-28-7P	625813-29-8P
	625813-30-1P	625813-31-2P	625813-32-3P
	625813-33-4P	625813-34-5P	625813-35-6P
	625813-38-9P	625813-39-0P	625813-45-8P
	625813-46-9P	625813-47-0P	625813-48-1P
	625813-50-5P	625813-51-6P	625813-59-4P
	625813-60-7P	625813-61-8P	625813-64-1P
	625813-65-2P	625813-67-4P	625813-68-5P
	625813-69-6P	625813-70-9P	625813-71-0P
	625813-72-1P	625813-73-2P	625813-74-3P
	625813-75-4P	625813-79-8P	625813-80-1P
	625813-82-3P	625813-83-4P	625813-84-5P
	625813-85-6P	625813-86-7P	625813-87-8P
	625813-88-9P	625813-90-3P	625813-91-4P
	625813-92-5P	625813-93-6P	625813-94-7P
	625813-95-8P	625813-96-9P	625813-97-0P
	625813-98-1P	625813-99-2P	625814-01-9P
	625814-02-0P	625814-03-1P	625814-04-2P
	625814-05-3P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl) benzenesulfonamides as dopamine receptor modulators for use as antipsychotic agents)


RN 625813-02-7 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-03-8 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-04-9 CAPLUS

CN Benzenesulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 625813-05-0 CAPLUS


CN Benzenesulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 625813-06-1 CAPLUS


CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-07-2 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-08-3 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-09-4 CAPLUS


CN Benzenesulfonamide, 4-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-12-9 CAPLUS


CN Benzenesulfonamide, 4-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-13-0 CAPLUS

CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)




RN 625813-14-1 CAPLUS

CN Benzenesulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)




RN 625813-15-2 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-16-3 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-19-6 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-20-9 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-21-0 CAPLUS

CN Benzenesulfonamide, N-methyl-3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-22-1 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-23-2 CAPLUS

CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 625813-24-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-25-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-26-5 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-27-6 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-28-7 CAPLUS

CN Benzenesulfonamide, 4-[(2-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-29-8 CAPLUS

CN Benzenesulfonamide, 4-[(2-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-30-1 CAPLUS

CN Benzenesulfonamide, 4-[(3-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-31-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-32-3 CAPLUS

CN Benzenesulfonamide, 4-[(3,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-33-4 CAPLUS

CN Benzenesulfonamide, 4-[(3,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-34-5 CAPLUS

CN Benzenesulfonamide, 4-[(2,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-35-6 CAPLUS

CN Benzenesulfonamide, 4-[(2,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-38-9 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-39-0 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-45-8 CAPLUS

CN Benzenesulfonamide, 4-[(2-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-46-9 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-47-0 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 625813-48-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-50-5 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-51-6 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-59-4 CAPLUS

CN Benzenesulfonamide, 3-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-60-7 CAPLUS

CN Benzenesulfonamide, 3-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-61-8 CAPLUS

CN Benzenesulfonamide, 3-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-64-1 CAPLUS

CN Benzenesulfonamide, 2-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-65-2 CAPLUS

CN Benzenesulfonamide, 2-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-67-4 CAPLUS


CN Benzenesulfonamide, 2-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 625813-68-5 CAPLUS

CN Benzenesulfonamide, 2-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-69-6 CAPLUS

CN Benzenesulfonamide, 2-(phenylmethoxy)-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 625813-70-9 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-71-0 CAPLUS


CN Benzenesulfonamide, 4-(phenoxy)methyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 625813-72-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-73-2 CAPLUS

CN Benzenesulfonamide, 4-(phenoxy)methyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-74-3 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-75-4 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-79-8 CAPLUS

CN Benzenesulfonamide, 4-(phenoxy)methyl)-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 625813-85-6 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-cyanophenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-86-7 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-acetylphenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-87-8 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-88-9 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 625813-90-3 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-methoxyphenyl)amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-91-4 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methylamino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 625813-92-5 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-chlorophenyl)methylamino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-93-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(4-methoxyphenyl)methylamino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-94-7 CAPLUS

CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[(4-fluorophenyl)methoxy]- (CA INDEX NAME)



RN 625813-95-8 CAPLUS


CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[(3-fluorophenyl)methoxy]- (CA INDEX NAME)



RN 625813-96-9 CAPLUS


CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[[4-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)

10/583,590



RN 625813-97-0 CAPLUS


CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[[4-(trifluoromethyl)phenyl]methyl]methylamino]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 625813-98-1 CAPLUS


CN Benzenesulfonamide, 4-[[4-(chlorophenyl)methyl]methylamino]-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 625813-99-2 CAPLUS


CN Benzenesulfonamide, 4-[[4-(chlorophenyl)methylamino]methyl]-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590



RN 625814-01-9 CAPLUS


CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 625814-02-0 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 625814-03-1 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]methylamino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)

10/583,590




● x HCl

RN 625814-04-2 CAPLUS
CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[(4-fluorophenyl)methoxy]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 625814-05-3 CAPLUS
CN Benzenesulfonamide, 4-[[[(4-chlorophenyl)methylamino]methyl]-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


IT	625814-07-5P	625814-08-6P	625814-09-7P
	625814-10-0P	625814-11-1P	625814-12-2P
	625814-13-3P	625814-14-4P	625814-15-5P
	625814-16-6P	625814-17-7P	625814-18-8P
	625814-19-9P	625814-20-2P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl) benzenesulfonamides as dopamine receptor modulators for use as antipsychotic agents)


RN 625814-07-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-methoxy-8-[[(4-nitrophenyl)sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 625814-08-6 CAPLUS


CN Benzenesulfonamide, 4-nitro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 625814-09-7 CAPLUS

CN Benzenesulfonamide, 4-nitro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625814-10-0 CAPLUS

CN Benzenesulfonamide, 4-amino-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625814-11-1 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-(bromomethyl)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 625814-12-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-[[[4-(4-fluorophenyl)amino]methyl]phenyl]sulfonyl]amino]-1,2,4,5-
tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 625814-13-3 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-(4-carboxyphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-,
3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 625814-14-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[[[4-(hydroxymethyl)phenyl]sulfonyl]amino]-,


1,1-dimethylethyl ester (CA INDEX NAME)




RN 625814-15-5 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 1,2,4,5-tetrahydro-7-[[[4-(hydroxymethyl)phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 625814-16-6 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-[[[4-[(4-chlorophenoxy)methyl]phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 625814-17-7 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-[[[4-(4-carboxyphenyl)sulfonyl]amino]-8-(dimethylamino)-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 625814-18-8 CAPLUS
 CN 3H-3-Benzazepine-3-carboxylic acid,
 7-[[[4-[[[(4-chlorophenyl)methylamino]carbonyl]phenyl]sulfonyl]amino]-8-
 (dimethylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX
 NAME)




RN 625814-19-9 CAPLUS
 CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]formylamino]-N-(2,3,4,5-
 tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625814-20-2 CAPLUS
 CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)amino]methyl]-N-(2,3,4,5-
 tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA
 INDEX NAME)

10/583,590



● HCl

OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:656751 CAPLUS

DOCUMENT NUMBER: 139:197391

TITLE: Preparation of N-heterocyclyl benzenesulfonamides as antipsychotic agents

INVENTOR(S): Bromidge, Steven Mark; Cooper, David Gwyn; Forbes, Ian Thomson; Gribble, Andrew Derrick; Johnson, Christopher Norbert; Lightfoot, Andrew P.; Moss, Stephen Frederick; Payne, Andrew H.; Rahman, Shahzad Sharooq; Witty, David R.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068752	A1	20030821	WO 2003-EP1545	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475783	A1	20030821	CA 2003-2475783	20030213
AU 2003215558	A1	20030904	AU 2003-215558	20030213
EP 1474399	A1	20041110	EP 2003-739495	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007557	A	20050104	BR 2003-7557	20030213
CN 1630642	A	20050622	CN 2003-803746	20030213
JP 2005526724	T	20050908	JP 2003-567883	20030213
IN 2004DN02106	A	20050401	IN 2004-DN2106	20040721
MX 2004007920	A	20041126	MX 2004-7920	20040813
NO 2004003794	A	20040910	NO 2004-3794	20040910
US 20050222124	A1	20051006	US 2005-504111	20050315
ZA 2004005804	A	20060531	ZA 2004-5804	20060317
PRIORITY APPLN. INFO.:			GB 2002-3437	A 20020213
			GB 2002-3438	A 20020213
			GB 2002-4758	A 20020228
			GB 2002-4784	A 20020228
			GB 2002-12548	A 20020530
			GB 2002-19711	A 20020823
			GB 2002-24466	A 20021021
			WO 2003-EP1545	W 20030213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197391

GI



AB The title compds. [I; A and B = (CH₂)_m and (CH₂)_n, resp.; R₁ = H, alkyl; R₂ = H, halo, OH, CN, etc.; R₃ = H, alkyl; Ar = (un)substituted Ph, monocyclic heteroaryl; R₄ = (un)substituted aryl or heteroaryl; Z = a bond, O, alkyl; Y = H, alkyl; m, n = 1-2; q = 1-3; r = 1-4] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared Thus, amidation of the amine II (preparation


given) with 4'-chloro-biphenyl-4-sulfonyl chloride followed by trifluoroacetyl group removal afforded III. The exemplified compds. I have pK_i values within the range of 6.6-9.6 at the dopamine D₃ receptor, and pK_i values within the range of 5.3-9.3 at the dopamine D₂ receptor. Pharmaceutical composition comprising the compound I was claimed.

IT 583044-69-3P 583044-71-7P 583045-10-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of benzenesulfonamides as antipsychotic agents)

RN 583044-69-3 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-71-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-10-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT	583044-70-6P	583044-72-8P	583044-73-9P
	583044-74-0P	583044-75-1P	583044-80-8P
	583044-81-9P	583044-82-0P	583044-83-1P
	583044-84-2P	583044-85-3P	583044-86-4P
	583044-87-5P	583044-88-6P	583044-89-7P
	583044-90-0P	583044-91-1P	583044-92-2P
	583044-93-3P	583044-94-4P	583044-95-5P
	583044-96-6P	583044-97-7P	583044-98-8P
	583044-99-9P	583045-00-5P	583045-01-6P
	583045-02-7P	583045-03-8P	583045-04-9P
	583045-05-0P	583045-06-1P	583045-07-2P
	583045-08-3P	583045-09-4P	583045-11-8P
	583045-12-9P	583045-13-0P	583045-43-6P
	583045-44-7P	583045-45-8P	583045-46-9P
	583045-47-0P	583045-48-1P	583045-49-2P
	583045-50-5P	583045-51-6P	583045-52-7P
	583045-53-8P	583045-54-9P	583045-55-0P
	583045-56-1P	583045-57-2P	583045-58-3P


583045-59-4P	583045-60-7P	583045-61-8P
583045-62-9P	583045-63-0P	583045-64-1P
583045-65-2P	583045-66-3P	583045-67-4P
583045-68-5P	583045-69-6P	583045-70-9P
583045-71-0P	583045-72-1P	583045-73-2P
583045-74-3P	583045-75-4P	583045-76-5P
583045-77-6P	583045-78-7P	583045-79-8P
583045-80-1P	583045-81-2P	583045-82-3P
583045-83-4P	583045-84-5P	583045-85-6P
583045-86-7P	583045-87-8P	583045-88-9P
583045-89-0P	583045-90-3P	583045-91-4P
583045-92-5P	583045-94-7P	583045-95-8P
583045-96-9P	583045-98-1P	583046-00-8P
583046-03-1P	583046-05-3P	583046-08-6P
583046-11-1P	583046-13-3P	583046-15-5P
583046-17-7P	583046-19-9P	583046-21-3P
583046-23-5P	583046-24-6P	583046-26-8P
583046-27-9P	583046-30-4P	583046-31-5P
583046-32-6P	583046-34-8P	583046-35-9P
583046-36-0P	583046-37-1P	583046-38-2P
583046-39-3P	583046-40-6P	583046-41-7P
583046-42-8P	583046-63-3P	583046-69-9P
583046-72-4P	583046-73-5P	583046-74-6P
583046-75-7P	583046-76-8P	583046-77-9P
583046-78-0P	583046-79-1P	583046-80-4P
583046-81-5P	583046-82-6P	583046-83-7P
583046-86-0P	583046-87-1P	583046-88-2P
583046-90-6P	583046-91-7P	583046-92-8P
583046-93-9P	583046-94-0P	583046-95-1P
583046-96-2P	583046-97-3P	583046-98-4P
583046-99-5P	583047-00-1P	583047-01-2P
583047-04-5P	583047-05-6P	583047-47-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzenesulfonamides as antipsychotic agents)

RN 583044-70-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-72-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



RN 583044-73-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 583044-74-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 583044-75-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 583044-80-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-81-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-82-0 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-83-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-84-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2',4'-dichloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-85-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-bromo-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-86-4 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-bromo-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-87-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-88-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-89-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-90-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2'-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-91-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2'-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-92-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 583044-93-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethoxy)- (CA INDEX NAME)



RN 583044-94-4 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(methylthio)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-95-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-96-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-97-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-98-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-99-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-00-5 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(2-thienyl)- (CA INDEX NAME)




RN 583045-01-6 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-02-7 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)



RN 583045-03-8 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)

10/583,590




RN 583045-04-9 CAPLUS

CN Benzenesulfonamide, 4-(2-naphthalenyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-05-0 CAPLUS

CN Benzenesulfonamide, 4-(2-benzofuranyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-06-1 CAPLUS


CN Benzenesulfonamide, 4-(4-pyridinyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-07-2 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-08-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-09-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583045-11-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-12-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 583045-13-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-43-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-nitro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-44-7 CAPLUS


CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-45-8 CAPLUS


10/583,590

CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-46-9 CAPLUS

CN Benzenesulfonamide, 4-(4-chlorophenoxy)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-47-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-48-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-49-2 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-50-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-51-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-52-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-53-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 2',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-54-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-55-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-56-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-57-2 CAPLUS


10/583,590

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-58-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-59-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 583045-60-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 583045-61-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4'-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590




RN 583045-62-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethoxy)- (CA INDEX NAME)




RN 583045-63-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-64-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-65-2 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-66-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-67-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(dimethylamino)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-68-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(dimethylamino)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-69-6 CAPLUS

CN Benzenesulfonamide, 4-phenoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-70-9 CAPLUS

CN Benzenesulfonamide, 4-phenoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-71-0 CAPLUS

CN Benzenesulfonamide, 4-(4-chlorophenoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-72-1 CAPLUS


CN Benzenesulfonamide, 4-(4-chlorophenoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-73-2 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4-(2-thienyl)- (CA INDEX NAME)

10/583,590




RN 583045-74-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4-(2-thienyl)- (CA INDEX NAME)




RN 583045-75-4 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-76-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-77-6 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)

10/583,590




RN 583045-78-7 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)




RN 583045-79-8 CAPLUS

CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-80-1 CAPLUS

CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-81-2 CAPLUS

CN Benzenesulfonamide, 4-(4-pyridinyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-82-3 CAPLUS

CN Benzenesulfonamide, 4-(4-pyridinyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-83-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-fluoro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-84-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-85-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 2,4'-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-86-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-87-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-88-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583045-89-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583045-90-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)




RN 583045-91-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)




RN 583045-92-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583045-94-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583045-95-8 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(2-thienyl)- (CA INDEX NAME)




RN 583045-96-9 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(3-thienyl)- (CA INDEX NAME)



RN 583045-98-1 CAPLUS


CN Benzenesulfonamide, 4-(3-furanyl)-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583046-00-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583046-03-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-05-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4'-(trifluoromethoxy)- (CA INDEX NAME)




RN 583046-08-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-11-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-3'-methoxy-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-13-3 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(2-thienyl)- (CA INDEX NAME)




RN 583046-15-5 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(3-thienyl)- (CA INDEX NAME)




RN 583046-17-7 CAPLUS

CN Benzenesulfonamide, 4-(3-furanyl)-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-19-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-21-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-23-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4'-(trifluoromethoxy)- (CA INDEX NAME)




RN 583046-24-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-26-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-3'-methyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-27-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-3-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-30-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-31-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 583046-32-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-34-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-35-9 CAPLUS

CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)



RN 583046-36-0 CAPLUS


CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)



RN 583046-37-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-38-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-39-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-40-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-41-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-42-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-63-3 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-69-9 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-72-4 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-73-5 CAPLUS

CN Benzenesulfonamide, 4-(4-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-74-6 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[[[(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583046-75-7 CAPLUS


CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[[[(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583046-76-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)

10/583,590




RN 583046-77-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-78-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)



RN 583046-79-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-difluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-80-4 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 2'-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-81-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-2'-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 583046-82-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(ethylthio)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583046-83-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-86-0 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4'-fluoro- (CA INDEX NAME)

10/583,590




RN 583046-87-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-88-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-90-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[8-(ethylthio)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4'-fluoro- (CA INDEX NAME)




RN 583046-91-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-piperidinyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-92-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)




RN 583046-93-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)



RN 583046-94-0 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(3-ethyl-2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-95-1 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583046-96-2 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-97-3 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583046-98-4 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-99-5 CAPLUS


CN Benzenesulfonamide, 4-[(3-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583047-00-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583047-01-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583047-04-5 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-2-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583047-05-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583047-47-6 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


IT 583047-07-8P 583047-33-0P 583047-34-1P
 583047-35-2P 583047-36-3P 583047-38-5P
 583047-40-9P 583047-41-0P 583047-42-1P
 583047-43-2P 583047-44-3P 583047-45-4P
 583047-46-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzenesulfonamides as antipsychotic agents)

RN 583047-07-8 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[4-iodophenyl)sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-33-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[4-iodophenyl)sulfonyl]amino]-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590




RN 583047-34-1 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-[(4-fluorophenyl)methyl]phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-35-2 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-1H-3-
benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 583047-36-3 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-(2,2,2-
trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583047-38-5 CAPLUS

10/583,590


CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[(3',4'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-
,1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-40-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-(5-chloro-2-thienyl)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-8-
methoxy-,1,1-dimethylethyl ester (CA INDEX NAME)




RN 583047-41-0 CAPLUS
CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-
1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 583047-42-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[(2-fluoro-4-iodophenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-,
1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590




RN 583047-43-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-(5-chloro-2-thienyl)-2-fluorophenyl]sulfonyl]amino]-1,2,4,5-
tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-44-3 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-2-fluoro-N-(2,3,4,5-tetrahydro-
8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 583047-45-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4'-chloro[1,1'-biphenyl]-4-yl]sulfonyl]amino]-8-(dimethylamino)-
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590



RN 583047-46-5 CAPLUS
CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT:	13	THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:656750 CAPLUS

DOCUMENT NUMBER: 139:197390

TITLE: Preparation of
7-arylsulfonamido-2,3,4,5-tetrahydro-1H-
benzo[d]azepines with 5-HT6 receptor affinity for the
treatment of CNS disorders

INVENTOR(S): Bromidge, Steven Mark; Johnson, Christopher Norbert;
Moss, Stephen Frederick; Rahman, Shahzad Sharooq;
Witty, David R.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068751	A1	20030821	WO 2003-EP1543	20030213
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003206909	A1	20030904	AU 2003-206909	20030213
EP 1487801	A1	20041222	EP 2003-704631	20030213
EP 1487801	B1	20060419		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005522452	T	20050728	JP 2003-567882	20030213
AT 323680	T	20060515	AT 2003-704631	20030213
ES 2260607	T3	20061101	ES 2003-704631	20030213
US 20050090485	A1	20050428	US 2004-503678	20040804
PRIORITY APPLN. INFO.:			GB 2002-3437	A 20020213
			GB 2002-4758	A 20020228
			GB 2002-12548	A 20020530
			GB 2002-19711	A 20020823
			WO 2003-EP1543	W 20030213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197390

GI



AB The title compds. [I; R1 = H, halo, OH, etc.; R2 = H, alkyl; m = 1-3; n = 1-4; A = (un)substituted Ph, naphthyl, monocyclic or bicyclic heteroaryl] and their pharmaceutically acceptable salts, useful in the treatment of CNS and other disorders such as depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment and schizophrenia, were prepared. E.g., a 4-step synthesis of I.HCl [R1, R2 = H; A = 3-F3CC6H4], starting from 7-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepine, was given. The exemplified compds. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values > 8 at human cloned 5-HT6 receptors. Pharmaceutical composition comprising the title compound I was claimed.


IT 585570-54-3P 585570-55-4P 585570-56-5P
 585570-58-7P 585570-59-8P 585570-60-1P
 585570-61-2P 585570-62-3P 585570-63-4P
 585570-64-5P 585570-65-6P 585570-66-7P
 585570-67-8P 585570-68-9P 585570-69-0P
 585570-70-3P 585570-83-8P 585570-84-9P
 585570-85-0P 585570-87-2P 585570-88-3P
 585570-89-4P 585570-90-7P 585570-91-8P
 585570-92-9P 585570-93-0P 585570-94-1P
 585570-95-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-arylsulfonamido-2,3,4,5-tetrahydro-1H-benzo[d]azepines with 5-HT6 receptor affinity for the treatment of CNS disorders)

RN 585570-54-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-55-4 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 585570-56-5 CAPLUS


CN Benzenesulfonamide, 3-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 585570-58-7 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-59-8 CAPLUS


CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590



RN 585570-60-1 CAPLUS


CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 585570-61-2 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-62-3 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-ethyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 585570-63-4 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 585570-64-5 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-65-6 CAPLUS


CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 585570-66-7 CAPLUS
CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-67-8 CAPLUS
CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-68-9 CAPLUS
CN Benzenesulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 585570-69-0 CAPLUS
CN Benzenesulfonamide, 4-bromo-N-(6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-70-3 CAPLUS
CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-83-8 CAPLUS
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)- (CA INDEX NAME)

10/583,590




RN 585570-84-9 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 585570-85-0 CAPLUS

CN Benzenesulfonamide, 3-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-87-2 CAPLUS


CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-88-3 CAPLUS


CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 585570-89-4 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 585570-90-7 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-ethyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-91-8 CAPLUS


CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-92-9 CAPLUS


CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)- (CA INDEX NAME)

10/583,590




RN 585570-93-0 CAPLUS

CN Benzenesulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-
(CA INDEX NAME)




RN 585570-94-1 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 585570-95-2 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT 585570-71-4P 585570-72-5P 585570-73-6P
585570-74-7P 585570-75-8P 585570-81-6P
585570-82-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 7-arylsulfonamido-2,3,4,5-tetrahydro-1H-benzo[d]azepines
with 5-HT₆ receptor affinity for the treatment of CNS disorders)


RN 585570-71-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 585570-72-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
1,2,4,5-tetrahydro-7-[(phenylsulfonyl)amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)




RN 585570-73-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,
7-[[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-
, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 585570-74-7 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 585570-75-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 585570-81-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[3,5-dichloro-2-methoxyphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 585570-82-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[4-bromo-2-(trifluoromethoxy)phenyl)sulfonyl]amino]-6-chloro-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:656734 CAPLUS

DOCUMENT NUMBER: 139:197389

TITLE: Preparation of benzenesulfonamides as antipsychotic agents

INVENTOR(S): Cooper, David Gwyn; Forbes, Ian Thomson; Gribble, Andrew Derrick; Lightfoot, Andrew P.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068732	A2	20030821	WO 2003-EP1544	20030213
WO 2003068732	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003218660	A1	20030904	AU 2003-218660	20030213
EP 1495004	A2	20050112	EP 2003-711891	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005517705	T	20050616	JP 2003-567865	20030213
US 20050085461	A1	20050421	US 2004-504110	20040810
PRIORITY APPLN. INFO.:				
			GB 2002-3435	A 20020213
			GB 2002-4721	A 20020228
			WO 2003-EP1544	W 20030213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197389

GI




AB The title compds. [I; A and B = (CH₂)_m and (CH₂)_n, resp.; R₁ = H, alkyl; R₂ = H, halo, OH, etc.; R₃ = H, alkyl; R₄ = halo, CF₃, OCF₃, alkyl, alkoxy, etc.; R₅, R₆ = H, halo, OH, CN, etc.; m, n = 1-2] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared. Thus, reacting the amine II with 4-n-butylphenylsulfonyl chloride in pyridine followed by treatment of the intermediate with 2M NH₃ in MeOH and H₂O afforded the title compound III. The exemplified compds. I showed pK_i values within the range of 7.1-9.4 at the dopamine D₃ receptor, and pK_i values within the range of 6.0-8.8 at the dopamine D₂ receptor.

IT 583025-17-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzenesulfonamides as antipsychotic agents)

RN 583025-17-6 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-
(CA INDEX NAME)




IT	583025-18-7P	583025-19-8P	583025-20-1P
	583025-21-2P	583025-22-3P	583025-26-7P
	583025-27-8P	583025-28-9P	583025-29-0P
	583025-30-3P	583025-31-4P	583025-32-5P
	583025-33-6P	583025-34-7P	583025-35-8P
	583025-36-9P	583025-37-0P	583025-38-1P
	583025-39-2P	583025-40-5P	583025-41-6P
	583025-42-7P	583025-43-8P	583025-44-9P
	583025-45-0P	583025-46-1P	583025-47-2P
	583025-48-3P	583025-49-4P	583025-50-7P
	583025-52-9P	583025-70-1P	583025-71-2P
	583025-72-3P	583025-73-4P	583025-74-5P
	583025-75-6P	583025-76-7P	583025-77-8P
	583025-78-9P	583025-79-0P	583025-80-3P
	583025-81-4P	583025-82-5P	583025-83-6P
	583025-84-7P	583025-85-8P	583025-86-9P
	583025-87-0P	583025-88-1P	583025-89-2P
	583025-90-5P	583025-97-2P	583026-89-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzenesulfonamides as antipsychotic agents)


RN 583025-18-7 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-19-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 583025-20-1 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 583025-21-2 CAPLUS
CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 583025-22-3 CAPLUS
CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 583025-26-7 CAPLUS
CN Benzenesulfonamide, 4-propyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-27-8 CAPLUS

CN Benzenesulfonamide, 4-propyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-28-9 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-29-0 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-30-3 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-31-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-32-5 CAPLUS

CN Benzenesulfonamide, 4-pentyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-33-6 CAPLUS


CN Benzenesulfonamide, 4-pentyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-34-7 CAPLUS


CN Benzenesulfonamide, 4-cyclohexyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-35-8 CAPLUS

CN Benzenesulfonamide, 4-iodo-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-36-9 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 583025-37-0 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 583025-38-1 CAPLUS


CN Benzenesulfonamide, 4-propoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-39-2 CAPLUS

CN Benzenesulfonamide, 4-propoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-40-5 CAPLUS

CN Benzenesulfonamide, 4-butoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-41-6 CAPLUS


CN Benzenesulfonamide, 4-butoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-42-7 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-43-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-44-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583025-45-0 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-ethyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-46-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-ethyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-47-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-propyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-48-3 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-propyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-49-4 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-50-7 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-52-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-70-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethoxy-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-71-2 CAPLUS


CN Benzenesulfonamide, 4-propyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-72-3 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-73-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-74-5 CAPLUS

CN Benzenesulfonamide, 4-pentyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-75-6 CAPLUS


CN Benzenesulfonamide, 4-cyclohexyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-76-7 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590




RN 583025-77-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 583025-78-9 CAPLUS

CN Benzenesulfonamide, 4-propoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-79-0 CAPLUS


CN Benzenesulfonamide, 4-butoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-80-3 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583025-85-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-86-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-87-0 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-88-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(2-thienyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583025-89-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-8-(2-thienyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583025-90-5 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[8-(2-furanyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583025-97-2 CAPLUS


CN Benzenesulfonamide, 4-cyclohexyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590

RN 583026-89-5 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT 583026-01-1P 583026-02-2P 583026-03-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzenesulfonamides as antipsychotic agents)


RN 583026-01-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583026-02-2 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-methyl-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583026-03-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/583,590



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/583,590

L20 ANSWER 69 OF 69 REGISTRY COPYRIGHT 2011 ACS on STN
RN 695815-10-2 REGISTRY
ED Entered STN: 18 Jun 2004
CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)
MF C22 H30 N2 O2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT